Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now early-phase tilt small index

Stage IIC Prostate Cancer AJCC v8: early-phase trial registry

5 of 16 indexed Stage IIC Prostate Cancer AJCC v8 trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,060 of 28,707 conditions by registered trial count.

16 US clinical trials · 5 currently recruiting · #1,060 of 28,707 conditions by registered trial count

Stage IIC Prostate Cancer AJCC v8: 16 US clinical trials tracked, 5 recruiting.

Stage IIC Prostate Cancer AJCC v8 is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 5 of these trials.

Enrollment posture brief

Registry condition stage-iic-prostate-cancer-ajcc-v8

OPEN 5 | RECR 31% | LATE 1 | EARLY 9 | RANK #1060 | SPON 5

Nearest open-share peer: Aortic Valve Disease (31% recruiting · 16 trials)

Adolescent62.5%Alcohol Intoxication56.3%AL Amyloidosis43.8%Stage IIC Prostate Cance (th…31%Allergy18.8%
Open-enrollment share among volume-matched conditions near Stage IIC Prostate Cancer AJCC v8

Stage IIC Prostate Cancer AJCC v8 lists 5 open slots (31% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Stage IIC Prostate Cancer AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Stage IIC Prostate Cancer AJCC v8 is recruiting below its size-band peers.

    5 of 16 indexed trials (31.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Stage IIC Prostate Cancer AJCC v8 research.

    M.D. Anderson Cancer Center accounts for 5 of 16 trials (31.3%). 10 distinct sponsors appear on at least one study for this condition label.

  3. Most Stage IIC Prostate Cancer AJCC v8 trials plan to enrol fewer than 100 people.

    Median target enrolment is 70 among the 16 trials that report a genuine target (sentinel values excluded). 10 of those (62.5%) plan for fewer than 100 participants.

  4. Stage IIC Prostate Cancer AJCC v8 research is mostly interventional.

    15 interventional and 1 observational studies make up this index (93.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 28Phase 31

Open and recent trials

16 total, page 1 of 1

RECRUITING Phase 2 200 participants

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

M.D. Anderson Cancer Center

NCT04947254

RECRUITING Phase 3 118 participants

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

Mayo Clinic

NCT06205316

RECRUITING Phase 2 70 participants

Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer

Ohio State University Comprehensive Cancer Center

NCT06330805

RECRUITING NA 52 participants

High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma

Jonsson Comprehensive Cancer Center

NCT04945642

RECRUITING Phase 2 30 participants

Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

Mayo Clinic

NCT07025369

ACTIVE NOT RECRUITING NA 208 participants

Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy, GARUDA Trial

Jonsson Comprehensive Cancer Center

NCT04624256

ACTIVE NOT RECRUITING 200 participants

Lifestyle Behavior Influences Among African American Patients With Stage 0-III Prostate Cancer Survivors and Their Partners

M.D. Anderson Cancer Center

NCT04189770

ACTIVE NOT RECRUITING Phase 2 141 participants

An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer

University of Washington

NCT04777071

ACTIVE NOT RECRUITING Phase 2 133 participants

White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA

City of Hope Medical Center

NCT04519879

ACTIVE NOT RECRUITING Phase 2 94 participants

RElugolix VErsus LeUprolide Cardiac Trial

Emory University

NCT05320406

ACTIVE NOT RECRUITING NA 64 participants

Watchful Living in Improving Quality of Life in Participants With Localized Prostate Cancer on Active Surveillance and Their Partners

M.D. Anderson Cancer Center

NCT03575832

ACTIVE NOT RECRUITING Phase 2 14 participants

Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer

Rutgers, The State University of New Jersey

NCT04253483

ACTIVE NOT RECRUITING NA 12 participants

Neoadjuvant Dietary Intervention in Intermediate Risk Prostate Cancer

M.D. Anderson Cancer Center

NCT04985565

ACTIVE NOT RECRUITING Phase 2 12 participants

Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery

Roswell Park Cancer Institute

NCT03899987

ACTIVE NOT RECRUITING NA 6 participants

Lifestyle Intervention for the Reduction of Prostate Cancer Disparities Among African Americans

M.D. Anderson Cancer Center

NCT04215029

COMPLETED Phase 1 22 participants

Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring

NRG Oncology

NCT04037254

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 8
Phase 3 1

Named interventions

Most-linked intervention names on Stage IIC Prostate Cancer AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Questionnaire Administration Other
4 trials
Quality-of-Life Assessment Other
3 trials
Biospecimen Collection Procedure
3 trials
Leuprolide Drug
2 trials
Informational Intervention Other
2 trials
High-Dose Rate Brachytherapy Radiation
2 trials
Niraparib Drug
2 trials
Hypofractionated Radiation Therapy Radiation
2 trials

US sites by state

Facility locations filed on Stage IIC Prostate Cancer AJCC v8 trials. A trial with sites in several states counts in each.

Texas 5 trials
California 4 trials
Arizona 3 trials
Georgia 2 trials
Wisconsin 1 trials
Washington 1 trials
Ohio 1 trials
New York 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Stage IIC Prostate Cancer AJCC v8 page

16 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 5 Stage IIC Prostate Cancer AJCC v8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • M.D. Anderson Cancer Center sponsors the most Stage IIC Prostate Cancer AJCC v8 trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage IIC Prostate Cancer AJCC v8 condition card totals 16 registered trials; most-linked intervention Questionnaire Administration; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.